Hypothesis Workshop
Develop, test and refine research hypotheses with AI assistance
Targeted Immunotherapy Efficacy in Triple-Negative Breast Cancer
Hypothesis Statement
IL-17 inhibitors combined with PD-L1 blockade will significantly increase progression-free survival in patients with metastatic triple-negative breast cancer compared to standard chemotherapy by enhancing tumor-specific T-cell responses.
Evidence Assessment
Refresh AnalysisKey Supporting Evidence
IL-17 Expression in Immune-Desert TNBC Microenvironment
Strong EvidenceYang et al. (2024) demonstrated elevated IL-17 expression in 78% of triple-negative breast cancer samples correlating with reduced TIL presence and poor prognosis.
PD-L1/IL-17 Axis in Murine Models
Moderate EvidenceChen et al. (2023) showed simultaneous inhibition of IL-17 and PD-L1 pathways resulted in 47% tumor regression in murine TNBC models versus 18% with PD-L1 inhibition alone.
AI-Suggested Study Design
Generated April 19, 2025Randomized Phase II Trial Design
Based on current evidence patterns, our AI suggests a randomized Phase II trial with the following structure:
Study Population
126 patients with metastatic TNBC who have progressed after first-line chemotherapy
Primary Endpoint
Progression-free survival at 12 months
Treatment Arms
1: IL-17 inhibitor + PD-L1 inhibitor
2: PD-L1 inhibitor + placebo
3:
Standard chemotherapy
Key Biomarkers
IL-17 receptor expression, TIL density, PD-L1 expression, circulating Th17 cells
DEfRAG AI Assistant
Based on my analysis of your hypothesis and current research, here are some suggested refinements:
Consider stratifying by IL-17 receptor expression levels—recent data suggests differential response based on expression thresholds.
Similar Research
IL-17 Blockade in Inflammatory Breast Cancer
Memorial Sloan Kettering Cancer Center
Dual Checkpoint Inhibition for TNBC
MD Anderson Cancer Center
Targeting Tumor Microenvironment in BRCA1+ Breast Cancer
Dana-Farber Cancer Institute
Collaboration Hub
Dr. Jennifer Miller (You)
Owner • Last active now
Dr. Robert Kim
Editor • Last active 2h ago
Dr. Sarah Johnson
Viewer • Last active yesterday
Activity Log
DEfRAG AI suggested experimental design
Today, 10:23 AM
Robert added new supporting evidence
Yesterday, 4:15 PM
Hypothesis statement refined
April 18, 2025
Initial hypothesis created
March 15, 2025
Other Active Hypotheses
Gut Microbiome Influence on Immunotherapy Response
StrongSpecific Bacteroides species abundance correlates with enhanced response to checkpoint inhibitors in melanoma.
Exosomal miRNA Biomarkers for Early Detection
ModeratePlasma exosomal miR-191 and miR-21 signature predicts pancreatic cancer 6-12 months before clinical diagnosis.
Ferroptosis Induction in Chemoresistant Tumors
ModerateGPX4 inhibition resensitizes platinum-resistant ovarian cancer cells through iron-dependent cell death.
AI-Generated Hypotheses
AIBased on your research interests, our AI has generated 7 novel hypotheses worth exploring.